The use of absorption enhancers to enhance the dispersibility of spray‐dried powders for pulmonary gene therapy
- 8 March 2005
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 7 (8), 1035-1043
- https://doi.org/10.1002/jgm.749
Abstract
Background Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we investigate whether certain absorption enhancers may also enhance the aerosolisation properties of spray-dried powders containing non-viral gene vectors. Methods Spray-drying was used to prepare potentially respirable trehalose-based dry powders containing lipid-polycation-pDNA (LPD) vectors and absorption enhancers. Powder morphology and particle size were characterised using scanning electron microscopy and laser diffraction, respectively, with gel electrophoresis used to assess the structural integrity of the pDNA. The biological functionality of the powders was quantified using in vitro cell (A549) transfection. Aerosolisation from a Spinhaler® dry powder inhaler into a multistage liquid impinger (MSLI) was used to assess the in vitro dispersibility and deposition of the powders. Results Spray-dried powder containing dimethyl-β-cyclodextrin (DMC) demonstrated substantially altered particle morphology and an optimal particle size distribution for pulmonary delivery. The inclusion of DMC did not adversely affect the structural integrity of the LPD complex and the powder displayed significantly greater transfection efficiency as compared to unmodified powder. All absorption enhancers proffered enhanced powder deposition characteristics, with the DMC-modified powder facilitating high deposition in the lower stages of the MSLI. Conclusions Incorporation of absorption enhancers into non-viral gene therapy formulations prior to spray-drying can significantly enhance the aerosolisation properties of the resultant powder and increase biological functionality at the site of deposition in an in vitro model. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2004
- Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler® and its absorption in healthy volunteersJournal of Controlled Release, 2004
- Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungsJournal of Controlled Release, 2004
- Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles1Diabetic Medicine, 2004
- Pulmonary Absorption Enhancement of Salmon CalcitoninJournal of Drug Targeting, 2004
- Physical Stability of Salmon Calcitonin Spray-Dried Powders for InhalationJournal of Pharmaceutical Sciences, 2004
- Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adultsCurrent Medical Research and Opinion, 2004
- Improvement of Insulin Absorption from Intratracheally Administrated Dry Powder Prepared by Supercritical Carbon Dioxide ProcessJournal of Pharmaceutical Sciences, 2003
- Pulmonary deposition of a budesonide/γ-cyclodextrin complex in vitroJournal of Controlled Release, 2003
- Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in ratsJournal of Pharmaceutical Sciences, 2003